A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies

Trial Profile

A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2017

At a glance

  • Drugs MGTA 456 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Novartis
  • Most Recent Events

    • 13 Oct 2016 Status changed from suspended to completed.
    • 06 Sep 2016 Status changed from recruiting to suspended.
    • 16 Aug 2016 Planned End Date changed from 1 Aug 2018 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top